AstraZeneca: Alzheimer Disease trials
The registry lists 24 Alzheimer Disease studies with AstraZeneca as lead sponsor. 0 are open to participants now and 5 have results posted.
Early Phase 1 1Phase 1 14Phase 2 5Phase 3 4No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease DementiaTerminatedNCT02972658Phase 3Results posted
- A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease DementiaTerminatedNCT02783573Phase 3Results posted
- An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's DiseaseTerminatedNCT02245737Phase 2/3Results posted
- Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy AdultsCompletedNCT02051335Phase 1Results posted
- SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.CompletedNCT02036645Phase 1Results posted
- A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293CompletedNCT02126514Phase 1
- AZD3293 Thorough QT Study in Healthy Male VolunteersCompletedNCT02040987Phase 1
- A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's PatientsCompletedNCT01795339Phase 1
- Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy VolunteersCompletedNCT01348737Phase 1
- An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's DiseaseCompletedNCT01325402Phase 1
- To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's DiseaseTerminatedNCT01125683Phase 2
- 4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT01039701Phase 2
- The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With DonepezilCompletedNCT01024660Early Phase 1
- To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid BurdenCompletedNCT00991419Phase 2
- Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ AmyloidCompletedNCT00838877Phase 1
- Study of Uptake, Break Down and Elimination of an Investigational Drug in Healthy VolunteersTerminatedNCT00777361Phase 1
- Pharmacokinetic Interaction Between AZD3480 and DonepezilTerminatedNCT00713765Phase 1
- Observational Study on Costs and Caregiver Burden in Alzheimer's DiseaseCompletedNCT00698165
- Drug Interaction Study Between AZD3480 and Cytochrome P450CompletedNCT00692510Phase 1
- Drug Interaction Study Between AZD3480 and WarfarinCompletedNCT00689637Phase 1
- Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy SubjectsCompletedNCT00689559Phase 1
- Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy SubjectsCompletedNCT00687141Phase 1
- Seroquel- Agitation Associated With DementiaCompletedNCT00621647Phase 3
- Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's DiseaseCompletedNCT00501111Phase 2